Horizon Therapeutics (HZNP) Misses Q2 EPS by 26c

Horizon Therapeutics (NASDAQ: HZNP) reported Q2 EPS of $1.07, $0.26 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $876.4 million versus the consensus estimate of $936.11 million.

GUIDANCE:

Horizon Therapeutics sees FY2022 revenue of $3.53-3.6 billion, versus the consensus of $3.96 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• Deutsche Bank monitors UK auto sales as Chinese exports grow